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Abstract
Despite the major advances in developing diagnostic techniques and effective treatments, atherosclerotic cardiovascular
disease (CVD) is still the leading cause of mortality and morbidity worldwide. While considerable progress has been
achieved to identify gene variations and environmental factors that contribute to CVD, much less is known about the
role of “gene–environment interactions” in predisposing individuals to CVD. Our chemical environment has significantly
changed in the last few decades, and there are more than 100,000 synthetic chemicals in the market. Recent large-scale
human population studies have associated exposure to certain chemicals including many endocrine disrupting chemicals
(EDCs) with increased CVD risk, and animal studies have also confirmed that some EDCs can cause aberrant lipid
homeostasis and increase atherosclerosis. However, the underlying mechanisms of how exposure to those EDCs
influences CVD risk remain elusive. Numerous EDCs can activate the nuclear receptor pregnane X receptor (PXR) that
functions as a xenobiotic sensor to regulate host xenobiotic metabolism. Recent studies have demonstrated the novel
functions of PXR in lipid homeostasis and atherosclerosis. In addition to directly regulating transcription, PXR has been
implicated in the epigenetic regulation of gene transcription. Exposure to many EDCs can also induce epigenetic modifica-
tions, but little is known about how the changes relate to the onset or progression of CVD. In this review, we will discuss
recent research on PXR and EDCs in the context of CVD and propose that PXR may play a previously unrealized role in EDC-
mediated epigenetic modifications that affect lipid homeostasis and atherosclerosis.
Key words: pregnane X receptor (PXR); epigenetics; cardiovascular disease (CVD); nuclear receptors; endocrine disrupting
chemicals (EDCs)
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Introduction
Atherosclerotic cardiovascular disease (CVD) is a leading cause
of mortality and morbidity worldwide [1]. Atherosclerosis is a
chronic inflammatory disease characterized by the accumula-
tion of lipids and inflammatory molecules in the subendothe-
lium of the artery, which can restrict blood flow and ultimately
lead to myocardial infarction and stroke. Atherosclerosis is a
complex chronic disease involving the interaction of genetic
and environmental factors over multiple years. Some people
are at a greater risk for developing CVD, and these risk factors
can be classified into either modifiable or non-modifiable. Non-
modifiable risk factors for developing CVD are age, gender, and
genetic heritability [2]. Modifiable CVD risk factors include
smoking, obesity, nutrition, hypertension, sedentary lifestyle,
stress, and hyperlipidemia [2]. Despite detection of atheroscler-
otic lesions in young children, the progression of atherosclero-
sis was long considered to begin during adolescence [3].
Interestingly, studies have also revealed factors influencing
CVD risk of the offspring. The number and size of fatty streaks
were significantly increased in fetal aortas from hypercholester-
olemia mothers during pregnancy [4]. In the ‘Fate of Early
Lesions in Children’ (FELIC) study, aortic lesions progressed
much faster in children from hypercholesterolemic mothers
than in normocholesterolemic mothers, even though both
groups of children had similar lipid profiles [3, 5]. Furthermore,
offspring from smokers had an adverse lipoprotein profile
compared with adults who had not been exposed in utero [6, 7],
suggesting that environmental factors can contribute to the
CVD risk of the exposed individuals’ offspring. While consider-
able progress has been achieved to identify risk factors that
contribute to CVD, the role played by “gene–environment inter-
actions” in predisposing individuals to CVD remains relatively
unexplored.
Endocrine Disrupting Chemicals in CVD
The chemical environment to which we are exposed has signifi-
cantly changed in the past few decades, and mounting evidence
has shown that endocrine disrupting chemicals (EDCs) can
interfere with an organism’s complex endocrine signaling
mechanisms and result in adverse consequences [8–11]. The US
Environmental Protection Agency defines an EDC as, “an exoge-
nous agent that interferes with synthesis, secretion, transport,
metabolism, binding action, or elimination of natural blood-
borne hormones that are present in the body and are responsi-
ble for homeostasis, reproduction, and developmental process”
[11]. A few examples of compounds that have been identified as
EDCs are polychlorinated biphenyls (PCBs), many pesticides, the
plastic base compound bisphenol A (BPA) and its structural ana-
logs, and numerous plasticizers such as phthalates and phtha-
late substitutes [11]. It was originally thought that EDCs act
primarily through nuclear hormone receptors; however, it is
now widely accepted that EDCs act through a variety of signal-
ing mechanisms, which include but are not limited to nuclear
steroid receptors, nonsteroid receptors, orphan receptors, epige-
netic modifications, and enzymatic pathways ultimately
responsible for maintaining endocrine homeostasis [11].
Although research on the health effects of EDCs in humans
initially focused primarily on reproduction and development,
recent findings have implicated EDC exposure to cardiometa-
bolic disease risk [11–25]. Sergeev et al. demonstrated that
people living within close proximity to sites contaminated
with organic pollutants compared to sites not containing any
identified hazardous waste had a 20% increase in acute myocar-
dial infarction hospital discharge rates [26]. Exposure to PCBs
induced hypercholesterolemia and promoted atherosclerosis in
animals [27–29]. Circulating PCB levels have been associated
with atherosclerotic plaques in the elderly [30]. BPA, a base
chemical used extensively in polycarbonate plastics in many
consumer products, has recently been associated with CVD in
several large and well-controlled cross-sectional and longitudi-
nal studies [13–15]. Independent studies have associated BPA
exposure with coronary atherosclerosis [31], carotid atheroscle-
rosis [32], and peripheral arterial disease [33], a subclinical
measure of atherosclerotic vascular disease. Consistently, BPA
exposure in elderly patients associates with inflammatory gene
expression [34]. These associations are independent of tradi-
tional CVD risk factors including body mass index, blood pres-
sure, lipid concentrations, and levels of physical activity [13, 15].
In addition to BPA, several phthalates and phthalate metabo-
lites have been associated with atherosclerosis. Phthalate
metabolites are associated with increased atherosclerosis in the
elderly [32]. However, the underlying mechanisms responsible
for these associations remain elusive, which continues to ham-
per rational assessment of the health risks of EDC exposure.
A multitude of genetic, nutritional, and environmental fac-
tors influence whether an individual is at risk of developing
obesity and metabolic disorders that affect CVD risk. Several
groups have shown that EDCs may act as “obesogens” to
increase the risk of obesity and diabetes [23, 35–38]. For exam-
ple, organotin compounds such as tributyltin chloride can
induce the differentiation of adipocytes in vitro and increase adi-
pose mass in vivo [22]. Recent studies demonstrated that expo-
sure to benzyl butyl phthalate (BBP) enhanced adipogenesis
thereby contributing to EDC-elicited adiposity [36]. Consistently,
BPA treatment enhanced hepatic fat deposition accompanied
by elevation of hepatic inflammation in CD-1 mice [39].
Exposure of p,p0-dichlorodiphenyldichloroethylene in rats exac-
erbates many aspects of the metabolic syndrome, including
dyslipidemia, glucose intolerance, and hypertension [37].
Verbanck et al. [35] described a potential role of BPA, bisphenol
F, and bisphenol S in altering global RNA expression in human
subcutaneous adipocytes. Collectively, these studies clearly
demonstrate a potential role for EDCs to contribute to the devel-
opment of cardiometabolic disease risk in humans.
Xenobiotic Receptor PXR and EDCs
Numerous EDCs including organochlorine and organophos-
phate pesticides, alkylphenols, phthalates, PCBs, and BPA and
its analogs have been identified to activate the nuclear receptor
pregnane X receptor (PXR) which functions as a xenobiotic sen-
sor to regulate xenobiotic metabolism [40–46] (Table 1). The abil-
ity of organisms to adapt to their surroundings and possess a
host defense mechanism against toxic chemicals is essential to
maintain life. PXR, also known as steroid and xenobiotic
receptor or SXR, was identified by three independent groups in
1998 [47–49] and was subsequently designated as NR1I2 (nuclear
receptor subfamily 1, group 1, member 2) in the standard
nomenclature [50]. Despite the different designations, this
receptor functions as a steroid and xenobiotic sensor to regulate
xenobiotic metabolism. Like other nuclear receptors, PXR con-
tains both an N’-terminal DNA-binding domain and a C’-termi-
nal ligand-binding domain (LBD), which are indispensable for
DNA binding and ligand binding as well as interaction with
co-regulators. PXR is activated by numerous endogenous hor-
mones, dietary steroids, pharmaceutical agents, and xenobiotic
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Table 1: EDCs that modulate human and/or rodent PXR activity
EDCs Human Rodent References
2-acetylaminofluorene þ þ [183]
2-(40-hydroxyphenyl)-2-phenylpropane þ  [42]
4-nonylphenol þ ND [184]
4-octylphenol þ ND [184]
a-hexachlorocyclohexane þ ND [184]
b-napthoflavone þ ND [184]
Aldrin þ  [185]
Alachlor þ þ [186, 187]
Acetyl tributyl citrate þ þ [76, 99]
Acetyl triethyl citrate þ ND [99]
Androstanol þ  [188]
Bisphenol A (BPA) þ  [42, 45]
Bisphenol B (BPB) þ  [42]
Benzophenone  þ [187]
Bisphenol AF (BPAF) þ  [42]
Brominated flame retardants (BDE) 28 þ ND [184]
BDE 47 þ ND [184]
BDE 99 þ ND [184]
BDE 100 þ ND [184]
BDE 153 þ ND [184]
BDE 209 þ ND [184]
Chlordecone þ  [185]
Chlorpyrifos þ  [185]
Cypermethrin þ  [185]
Cyperoterone acetate  þ [189]
Decamethylcyclopentasiloxane þ ND [184]
Dibutyl phthalate þ þ [190]
Dichlorodiphenyltrichloroethane þ  [184, 185]
o,p0-Dichlorodiphenyltrichloroethane þ þ [185, 191]
Dichlorodiphenyldichloroethylene þ þ [184, 192]
di(2-ethylhexyl) phthalate (DEHP) þ þ [44, 45, 76]
Dieldrin þ  [184, 185]
diethyl phthalate (DEP) þ ND [182]
Diflubenzuron þ  [186]
Digoxin þ  [45]
di-isobutyl phthalate (DiBP) þ ND [182]
diisononyl phthalate (DiNP) þ ND [76, 182]
di-n-butyl phthalate (DnBP) þ ND [99, 182]
Endosulfan þ  [184, 185]
Endrin þ  [185]
Fenarimol þ  [186]
Fenbuconazole þ  [186]
Fenvalerate þ  [185]
Fipronil þ  [186]
Hexabromocyclododecane (HBCD) mix: a-HBCD (10%); b-HBCD (9%); c-HBCD (81%) þ ND [184]
Hexamethylcyclotrisiloxane þ ND [184]
Imazalil þ  [186]
Isoproturon þ  [186]
Lindane þ þ [184, 185]
MEHP þ þ [193]
Methoxychlor  þ [184, 185, 187]
Metolachlor þ  [186]
Myclobutanil  þ [194]
Nonylphenol  þ [44]
Octamethylcyclotetrasiloxane þ ND [184]
Oxadiazon þ  [186]
Permethrin þ  [186]
PentaBDE mix: BDE 47 (42%); BDE99 (34%); BDE100 (9%); BDE153 (2%); BDE154 (2%) þ ND [184]
Pentachlorophenol þ  [185]
Perflurononanoic acid þ ND [184]
Polybrominated diphenyl ether (PBDE) (47, 99, and 209) þ þ [195, 196]
Polychlorinated biphenyl (PCB) 47 þ þ [184, 189]
continued
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chemicals (Table 1) [40, 41, 46]. It functions as a heterodimer
with the retinoid X receptor (RXR) to modulate gene transcrip-
tion [51, 52]. PXR was initially characterized based on the obser-
vation that ligands activating the receptor can induce
cytochrome P450 monooxygenase 3A4 (CYP3A4) expression.
Consequently, it was further identified that PXR transcription-
ally regulates CYP3A4 [48, 49, 53]. Similar to the CYP enzymes,
PXR is highly expressed in the liver and intestine [47–49, 53],
two main sites of the host defense against toxic xenobiotics.
The discovery of PXR led to the identification of many novel tar-
get genes involved in detoxification and transport of lipophilic
compounds, such as genes that encode Phase I (e.g. CYP450s)
and Phase II (e.g. glutathione transferase) detoxification
enzymes, as well as the ABC family transporters [e.g. multidrug
resistance 1 (MDR1)]. Collectively, PXR has also been shown to
be a critical regulator for other processes, such as modulating
lipid levels, atherogenesis, and inflammation.
Since the initial discovery of PXR, many orthologs have been
cloned from a wide variety of species, including Drosophila [54],
Caenorhabditis elegans [55], and different types of mammals (e.g.
human, mouse, rat, rabbit, monkey) [47–49, 53, 55–58]. In
Drosophila, the PXR ortholog was identified as DHR96 [54]. In C.
elegans, three orthologs of PXR are represented as DAF12, NHR-
8, and NHR-48 [55]. Compared with most other nuclear recep-
tors, PXR is remarkably divergent across mammalian species
with the LBDs sharing only 60–80% identity compared with
the 90% typically exhibited by orthologous nuclear receptors
[41, 46]. PXR exhibits significant differences in its pharmacology
across species (e.g. mouse vs. human) [41, 48, 59, 60]. The known
species differences in CYP3A induction observed in vivo appears
to be partially attributed to the different pharmacology of PXR.
For example, pregnenolone 16a-carbonitrile (PCN), a known
CYP3A inducer in rodents, acts as a potent agonist of mouse
and rat PXR but does not activate human PXR [46, 60]. By con-
trast, rifampicin, a known inducer of CYP3A in humans and rab-
bits, does not activate mouse PXR [46, 59, 60]. In addition to its
species-specific responses, some ligands can activate PXR in a
tissue-specific manner [46, 61–63]. For example, rifaximin, a
clinically used antibiotic drug, can only activate human PXR in
the intestine but not in the liver [62]. Some forms of vitamin E,
such as tocotrienols, can selectively regulate PXR target genes
in hepatic and intestinal cell lines [46, 61]. Collectively, these
studies suggest that PXR can regulate species- and tissue-
specific responses to xenobiotic exposure.
A fundamental question concerning all EDC studies is
whether low-dose exposure to EDCs can affect human endo-
crine functions, leading to adverse effects [42]. For example,
recent studies have demonstrated that BPA can activate human
PXR in vitro at relatively high doses (2 lM) [42]. However, BPA
and analogues have been shown to be able to synergistically
activate human PXR in vitro [42]. Therefore, combinations of BPA
and other EDCs may activate human PXR in vivo at a much lower
dose. In addition, several groups have measured unconjugated
BPA in human urine samples and found that BPA concentra-
tions range from undetectable to 2.5 ng/ml [64–67]. By compari-
son, mice fed diet supplemented with BPA at a dose of 50 mg/kg
for 12 weeks had approximately 2 ng/ml of unconjugated BPA in
the urine [66], well within the human range. These animals also
exhibited an elevated xenobiotic response with BPA exposure
[66]. Many of these EDCs are lipophilic compounds, which can
accumulate in adipose tissue; BPA and its analogues, for exam-
ple, were found in 55% of breast adipose tissue samples from
women [68]. It has been predicted that many classes of EDCs
accumulate in the lipid droplet of adipocytes, which may result
in high concentrations in the fat depot [69, 70]. Therefore, even
if an individual EDC may not reach sufficient concentrations to
Table 1: Continued
EDCs Human Rodent References
PCB 97 þ ND [184]
PCB 101 þ ND [184]
PCB 118 þ ND [184, 197]
PCB 151 þ ND [184]
PCB 153 þ þ [43, 184, 197, 198]
PCB 170 þ ND [184]
PCB 183 þ ND [184]
PCB 184 þ þ [43, 184, 189]
PCB 188 ND þ [189]
PCB 190 þ ND [184]
PCB 194 þ ND [198]
PCB 196  þ [43, 189]
PCB 197 þ þ [43]
PCB 200 ND þ [189]
PCB 201 þ þ [43]
PCB 209 þ þ [43]
Prochloraz þ  [186]
Propiconazole þ þ [186, 194]
Pretilachlor þ  [186]
Tetrabromobisphenol A þ ND [184]
Trans-nonachlor þ þ [185, 189, 199]
Triadimefon  þ [194]
Tributyl citrate þ þ [76, 99]
Triclosan þ  [197]
Trifluralin  þ [187]
Vinclozolin  þ [184, 187]
EDCs that activate human or rodent PXR are indicated by “þ” and EDCs that do not modulate PXR activity are indicated by “.” ND, not determined.
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activate PXR in some tissues, the accumulation of this EDC in
certain tissues and the synergistic effects of this and other EDCs
may still lead to the activation of PXR.
Role of PXR in Mediating the Adverse Effects of
EDCs on CVD
The identification of PXR as a xenobiotic sensor has provided an
important tool for the study of new mechanisms through which
EDC exposure impacts disease development. While the role of
PXR in xenobiotic metabolism has been well studied by many
laboratories, recent studies have demonstrated novel functions
of PXR in CVD [46, 66, 71–76]. Many clinically relevant PXR
ligands have been shown to elevate plasma lipid levels in
patients and increase their CVD risk [71, 77–81]. For example,
treatment with rifampicin, a PXR ligand used in the clinic for
the treatment of tuberculosis, can cause hyperlipidemia [77],
and short-term treatment increased the ratio of lathosterol to
cholesterol, indicative of increased cholesterol synthesis [82].
Treatment with ritonavir and amprenavir, HIV protease inhibi-
tors and potent PXR activators [75, 83], induced hyperlipidemia
and was also associated with increased risk of CVD in HIV
patients [78, 79, 84, 85]. Furthermore, a meta-analysis of seven
genome-wide association studies found that the common
genetic variants in PXR are associated with plasma low-density
lipoprotein (LDL) cholesterol levels in humans [73].
PXR has also been demonstrated to have pro-atherogenic
effects in multiple animal models [71, 72]. Chronic activation of
PXR elicited by feeding mice the mouse PXR ligand PCN led to
increased levels of total plasma cholesterol and atherogenic lip-
oproteins very low-density lipoprotein and LDL in wild-type
(WT) mice, but not in PXR-deficient (PXR/) mice [71], suggest-
ing that the PCN-mediated effects were through PXR signaling.
de Haan et al. [74] demonstrated that activation of PXR by PCN
treatment increased plasma total cholesterol and very low-
density lipoprotein levels in apolipoprotein E (ApoE)*3-Leiden
mice which exhibit a human-like lipoprotein distribution on a
cholesterol-rich diet. PCN-mediated PXR activation also
decreased high-density lipoprotein cholesterol levels in ApoE*3-
Leiden cholesteryl ester transfer protein (CETP) transgenic mice
[74]. Another study showed that short-term exposure to the HIV
protease inhibitor, amprenavir, which activates PXR by oral
delivery, significantly increases plasma total cholesterol and
LDL cholesterol levels in WT mice [75]. By contrast, amprenavir
did not affect plasma cholesterol levels in PXR/mice [75], indi-
cating a potential role of PXR in mediating adverse effects on
lipid homeostasis of relevant antiretroviral drugs. In addition to
dyslipidemia, chronic PXR activation also significantly
increased atherosclerotic lesion sizes in ApoE/ mice [71]. By
contrast, PXR loss-of-function decreased atherosclerosis in
ApoE/ mice in part due to decreased fatty acid transporter
CD36 expression and CD36-mediated lipid uptake in macro-
phages [72]. All of the evidence suggests that modulation of PXR
can affect lipid metabolism and atherosclerosis in different ani-
mal models.
In addition to clinically used drugs such as rifampicin and
amprenavir, recent studies have also revealed the role of PXR in
mediating EDCs’ impact on lipid homeostasis and atherosclero-
sis. For example, several large-scale human studies indicate
that exposure to BPA may increase CVD risk or atherosclerosis
development [13–15, 31, 32]. BPA is a weak agonist of the estro-
gen receptor (ER), and most studies on BPA have focused on its
estrogenic effects [86, 87]. However, the estrogenic effects of
BPA may not explain the link between BPA exposure and CVD
risk since numerous human and animal studies have demon-
strated the protective effects of estrogen against atherosclerosis
or CVD [11, 88–91]. In addition to activating ER, BPA and several
of its analogs have been identified as potent agonists for PXR
[42]. Interestingly, BPA can strongly activate human PXR but
does not affect mouse or rat PXR activity [42], indicating the
importance of utilizing appropriate animal models to evaluate
BPA’s risk assessment in humans. To investigate the effects of
BPA exposure on atherosclerosis development, a PXR-
humanized ApoE-deficient mouse model has been generated
[66] and exposure to BPA significantly increased atherosclerosis
in mice expressing human PXR, but not in littermates without
human PXR [66]. BPA-mediated human PXR activation also
increased CD36 expression, lipid accumulation, and foam cell
formation in macrophages of PXR-humanized ApoE-deficient
mice [66]. In addition to mouse models, Fang et al. also demon-
strated that chronic BPA exposure induced metabolic disease
and atherosclerosis in hyperlipidemic rabbits [92, 93]. Since BPA
can activate rabbit PXR as well as human PXR, it is plausible
that PXR signaling may also contribute to those adverse effects
in rabbits. Overall, these studies suggest that BPA-mediated PXR
activation may potentially accelerate atherosclerosis develop-
ment in humans, which provide a potential molecular mecha-
nism that links BPA exposure to increased risk of CVD in
exposed individuals.
The adverse effects of BPA and several phthalate plasticizers
[e.g. di-(2-ethylhexyl)phthalate, DEHP] on human health have
attracted considerable attention and engendered controversy in
the past few decades, partly due to their endocrine-disrupting
properties. In addition to these well-known EDCs, there are
many phthalate substitute plasticizers that have not been well
studied for endocrine disruption [17, 94–96]. For example, citrate
esters, including TBC, acetyl tributyl citrate (ATBC), and triethyl
citrate, represent a large group of plasticizers that have been
approved by the FDA to be used in food packaging materials,
vinyl toys, medical devices, cosmetics, and pharmaceutical
drugs [94, 95, 97, 98]. Several citrate esters including TBC and
ATBC have been identified as potent and selective PXR agonists
[76, 99] (Table 1). Similar to rifaximin, TBC activates intestinal
PXR but does not affect hepatic PXR activity [76]. Interestingly,
short-term TBC treatment increased plasma total cholesterol
and atherogenic LDL cholesterol levels in WT mice but did not
affect lipid levels in PXR-deficient mice [76]. In addition to fatty
acid transporter CD36, activation of PXR by TBC stimulated
intestinal expression of Niemann–Pick C1-Like 1 (NPC1L1), an
essential transporter in mediating intestinal cholesterol uptake
in the gut [100–102]. TBC promoted cholesterol uptake by both
murine and human intestinal cells in a PXR-dependent manner
[76]. In addition to NPC1L1, several other studies demonstrated
that PXR might regulate other key intestinal genes mediating
lipid uptake and transportation including CYP27A1, ABCA1, gas-
tric lipase, lysosomal lipase, and diacylglycerol acyltransferase
1 and 2 [46, 75, 103–106]. Therefore, activation of PXR by expo-
sure to EDCs such as TBC may lead to aberrant lipid homeosta-
sis, thereby inducing dyslipidemia and increasing the risk of
CVD in exposed individuals.
EDC-Elicited Epigenetic Modifications That
Influence CVD Risk
The term epigenetics refers to the reversible heritable altera-
tions in gene expression that are not due to changes in the DNA
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sequence. Epigenetic modifications, such as DNA methylation,
histone modifications, and noncoding RNAs, alter chromatin
structure and/or DNA accessibility therefore regulating gene
expression [107]. These processes, regulated by environmental
and dietary cues, are essential for proper development. Recent
studies have revealed an important role of epigenetic modifica-
tion in CVD [108–110]. In this section, we will mainly discuss the
impact of EDC exposure on epigenetic modifications in the con-
text of CVD.
DNA Methylation
DNA methylation is an epigenetic mark that adds a covalently
bound methyl group (-CH3) to sites in the genome where cyto-
sine is followed by guanine to generate “CpG” islands. Most CpG
dinucleotides in the human genome are methylated and are
mostly associated with a reduction in gene expression [111].
Changes in DNA methylation patterns have emerged in patients
and animal models of CVD.
Differential methylation patterns were first discovered in
atherosclerotic lesions of rabbits in the late 1990s. Laukkanen
et al. [112] discovered marked hypomethylation of the extracel-
lular superoxide dismutase gene in atherosclerotic aortas of
rabbits. Consistently, the same group also identified a decrease
in genomic 5-methylcytosine content in advanced human,
mouse, and rabbit atherosclerotic lesions [113]. Both hyperme-
thylation and hypomethylation were detected in mice prior to
no detectable changes in atherosclerotic lesions [114]. Lund
et al. [114] also discovered that treatment with atherogenic lipo-
proteins promote global DNA hypermethylation in human
monocytes. Differential methylation patterns have been identi-
fied on CVD-associated genes, such as ERa [115], ERb [116],
Niemann–Pick type C1 [117], ATP-binding cassette A1 [118],
sterol regulatory element–binding protein 1 [119], LDL receptor
[119], and the monocarboxylate transporter gene [120]. The
impact DNA methylation has on CVD including cardiac hyper-
trophy, heart failure, and arrhythmias has been discussed in
detail in another review [108]. While these experimental obser-
vations link methylation pattern changes to CVD, the contribu-
tion of EDC exposure to these changes is not well defined.
Several PXR agonistic EDCs have also been demonstrated to
cause epigenetic changes that may increase CVD risk. For exam-
ple, in utero exposure to the PXR agonist DEHP [76, 121] results in
hypermethylation of the glucose transporter 4 in F1 offspring of
rats, which likely contributes to the exacerbated cardiometa-
bolic disease state of those animals [122]. It was later discovered
by the same group that gestational feeding of DEHP also caused
global DNA hypermethylation of genes involved in the develop-
ment and function of pancreatic b-cells [123], which may also
lead to increased CVD risk. Higher urinary concentrations of
another EDC, BPA, in prepubescent girls were associated with
decreased global methylation, which corresponded to changes
in the expression of genes involved in inflammation and metab-
olism [124]. In an HFD-driven rat steatosis model, in utero BPA
exposure altered methylation within the carnitine
palmitoyltransferase (CPT) 1a gene leading to hepatic deposi-
tion of triglycerides [125]. Garcia-Arevalo et al. [126] investigated
the impact of exposure to BPA during pregnancy on body
weight, glucose homeostasis, and gene expression in several
major organs in male offspring. They found that in utero expo-
sure to BPA elicited hyperglycemia, glucose intolerance,
increased plasma non-esterified fatty acids and hepatic trigly-
ceride levels [126]. BPA treatment also affected the expression
of the several key genes involved in lipid and fatty acid
metabolism including SREBP-1c, PPARa, and CD36 in the off-
spring [126]. In another study, the same group found that in
utero BPA exposure influenced the expression of genes involved
in b-cell development, which may contribute to the impaired
glucose tolerance observed in adult offspring [127]. Although
the DNA methylation status of those genes was not investi-
gated, it is likely that in utero BPA exposure affects the DNA
methylation to induce those changes. There are many more
studies investigating the impact of BPA exposure on epigenetic
changes and metabolic diseases, which have been discussed in
detail in a comprehensive review [128]. In addition to these
genes related to CVD risk, PXR promoter methylation can also
be modulated by ligands or during pathophysiological disease
conditions [129–131]. However, it remains to be determined
whether those PXR agonist EDCs can mediate epigenetic modu-
lation of the PXR gene itself to influence CVD risk.
Histone Acetylation
Lysine acetylation, controlled by histone acetyltransferases
(HATs) and histone deacetylases (HDACs), was first identified as
histone modifiers that regulate DNA accessibility and chroma-
tin structure to control gene transcription [132, 133]. This proc-
ess is now known to occur in more than 80 transcription factors
and various cytoplasmic proteins [132, 133]. The acetylation pat-
tern varies from one protein to another, and the effects can be
multifaceted for one protein [132, 133]. Many studies have
revealed a role for both HATs and HDACs in regulating genes
that are involved in CVD initiation and progression [134, 135],
and we highlight a few of these studies below.
HDACs are closely linked to the progression of atherosclero-
sis, and inhibition of HDACs prevents the progression of athero-
sclerosis [136]. Local administration of the HDAC inhibitor,
trichostatin A (TSA), significantly suppressed neointimal hyper-
plasia [136, 137]. HDAC inhibition has also been shown to sup-
press vascular smooth muscle cell proliferation and ultimately
neointima formation [138, 139]. In addition, common genetic
variants of some HDACs may also increase genetic susceptibil-
ity to ischemic stroke and CVD [140]. For example, HDAC9 was
upregulated in human atherosclerotic plaques [141], and dele-
tion of HDAC9 alleviated atherosclerosis in mice [142, 143]. In
contrast, Choi et al. [144] demonstrated that HDAC inhibition
with TSA exacerbated atherosclerosis in LDL receptor–deficient
mice.
While these studies revealed an important regulatory role
for HDACs in CVD, only a few studies have investigated the
impact of EDCs on histone acetylation related to CVD. Yeh et al.
[145] demonstrated that exposure to EDCs, nonylphenol, and 4-
octylphenol suppressed LPS-induced inflammatory gene
expression in human-derived THP-1 monocytes. Furthermore,
LPS-elicited histone 4 acetylation at the IFN-a-inducible protein
10 (IP10) and the monocyte-derived chemokine gene loci were
reduced after exposure to these EDCs [145]. It is worth noting
that nonylphenol is also a PXR agonist [44] (Table 1), and PXR
activation has been well documented to suppress inflammation
[146]. Therefore, it would be interesting to determine whether
EDC-mediated activation of PXR can affect histone acetylation
to influence CVD risk in the future.
Noncoding RNA
While the majority of the human genome is transcribed, only
2% of these transcripts are translated into protein [147]. For
many years, the scientific community regarded the other 98% of
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non-translated transcripts to be “junk,” but the functions of
these non–protein-coding RNAs (ncRNAs) are now being
revealed in many diseases, including cancer [148] and CVD
[149]. The ncRNAs can be classified into microRNAs (miRNAs),
short interfering RNAs (siRNAs), PIWI-interacting RNAs
(piRNAs), XCL inactivation-linked small RNAs (XiRNAs), and
long ncRNAs. These different ncRNAs can be defined based on
their length, target of interest, and function. Long ncRNAs, for
example, are longer than 200 nucleotides, whereas the other
ncRNAs are less than 45 nucleotides. There is a host of literature
surrounding the influence of long ncRNAs on epigenetic proc-
esses [150], but this review will focus on the most widely
studied ncRNA in CVD, miRNAs.miRNAs are short ncRNAs that
bind to complementary regions in their target genes, often in
the 30-UTR regions and suppress their translation and/or facili-
tate degradation [151, 152]. miRNAs control epigenetic modifica-
tions, such as establishing DNA methylation through regulation
of key DNA methylation enzymes [153–158]. Moreover, miRNAs
may control DNA accessibility via regulation of chromatin
structure by regulating histone acetylase/deacetylase enzymes
[155, 159, 160]. Mounting evidence has identified several key
miRNAs in the development of CVD (for a thorough review on
all miRNAs in CVD, see Barwari et al. [161]); however, little is
known about the environmental factors influencing miRNA-
mediated CVD risk.
Evidence linking EDC exposure to differential miRNA expres-
sion and CVD risk has been recently reported. Wahlang et al.
[162] demonstrated that human endothelial cell exposed to the
PCB mixture Aroclor 1260 significantly altered 557 out of 6658
miRNAs, and 21 of these miRNAs were found to be associated
with vascular diseases. Aroclor 1260 exposure increased miR-
21, miR-31, miR-126, miR-221, and miR-222 expression levels
[162]. Interestingly, elevated miR-21 levels have been reported
in cardiac injury [163] and miR-126 and miR-31 levels have been
demonstrated to alter inflammation [164]. Other groups have
demonstrated the impact of EDC exposures on differential
miRNA expression in the central nervous system, reproductive
axis, as well as metabolic regulation [165]. However, more work
is required to understand how EDCs alter the miRNA profile in
atherosclerosis and hyperlipidemia.
Epigenetic Regulation of PXR Expression
In addition to the well-described ligand-dependent mechanism,
transcriptional activity of PXR can also be epigenetically regu-
lated. Studies have demonstrated the impact of EDC exposure
on the epigenetic modification of genes related to cardiometa-
bolic disease [122, 123, 125, 145, 162]. It is plausible that these
EDCs can also epigenetically modulate PXR expression to influ-
ence CVD risk. For example, changes of PXR promoter methyla-
tion has been demonstrated under different conditions in mice
and humans [129–131]. In females with intrahepatic cholestasis
of pregnancy compared to healthy pregnant women, the distal
PXR promoter (1224 bp) was significantly hypomethylated,
which was positively correlated with bile acid composition
[129]. Moreover, differential PXR promoter methylation was
observed in a variety of colon cancer cells, which might be asso-
ciated with interindividual variability of drug toxicity [130].
PXR has also been demonstrated to be epigenetically
regulated by microRNAs. Takagi et al. [166] measured PXR mes-
senger RNA (mRNA) and protein levels in 25 human livers and
found that mRNA and protein levels were not correlated, sug-
gesting posttranscriptional regulation of PXR. Furthermore, 16
miRNA binding sites were found in the 30-UTR in human PXR
[166]. MiR-148a was then identified as a critical regulator of
human PXR expression [166]. Overexpression of miR-148a
suppressed PXR protein levels and, in contrast, inhibition of
miR-148a elicited increases in PXR protein expression [166]. A
similar binding site was discovered in human CYP3A4; however,
CYP3A4 was unresponsive to miR-148a overexpression [166].
Although the 30-UTR of PXR is not well conserved between spe-
cies, the miR-148a element has been identified in both mice and
rats, suggesting that this specific miRNA may control PXR gene
expression in other mammals [166].
In another human cohort study, genetic variants in the 30-
UTR of PXR were identified in specific genes involved in xenobi-
otic metabolism [152]. For example, bioinformatics analysis
revealed that 1025 unique miRNAs were predicted to bind to the
30-UTR of hPXR mRNA [152]. Furthermore, the PXR target gene
CYP3A4 was predicted to be regulated by 889 unique miRNAs
[152]. The variant rs1054190C of PXR may result in a new binding
site for miR1250-5p [152]. In contrast, the variant rs1054191G
was predicted to result in the loss of a binding site for miR-
371 b-3p, miR-4258, and miR-4707 [152]. More recently,
Vachirayonstien and Yan [167] tested 58 miRNAs and identified
miR-30c-1-3p as a silencer of PXR expression. Many PXR SNPs
have been identified to be significantly associated with plasma
LDL cholesterol levels in humans, many of which were found in
the 30-UTR of PXR mRNA [73]. It is possible that these SNPs
affect miRNA binding to PXR mRNA, leading to altered lipid
homeostasis and changed LDL levels. Although there may be
other regulatory miRNAs targeting PXR, the physiological conse-
quence on PXR stability and the impact of these identified
miRNAs and other potential miRNAs on lipid metabolism have
not been investigated.
Potential Role of PXR in Epigenetic Regulation
of Gene Transcription
In addition to binding to its responsive motifs and transcrip-
tionally regulating target gene expression, a few studies have
indicated a potential role of PXR in epigenetic regulation of mul-
tiple targets. Cui et al. [168] performed an unbiased investigation
of PXR DNA-binding motifs and their genomic locations by
using chromatin immunoprecipitation (ChIP)-Seq approach in
mouse livers. Surprisingly, PXR can bind to similar regions of
DNA as the epigenetic mark of gene activation, H3K4Me2 [168].
By contrast, PXR binding did not overlap with H3K27Me3, an epi-
genetic mark of gene repression. Unlike strong enrichment of
H3K4Me2 on the prototypical PXR target gene Cyp3A11, another
PXR-regulated gene involved in lipid metabolism, CD36, was not
enriched with H3K4Me2. Cui et al. [168] suggested that a permis-
sive epigenetic mark is absent, and thus, PXR binding is masked
in the chromatin and binding is unable to occur. A more recent
study demonstrated that PXR ligand rifampicin treatment can
lead to increased levels of H3K4me3 and H3 acetylation and
decreased levels of H3K27me3 in the CYP3A4 promoter in
human intestinal LS174T cells [169]. Consistently, knockdown
of PXR abolished the changes of those epigenetic changes in the
promoter [169]. In another study using human primary hepato-
cytes, Smith et al. [170] found that PXR was significantly
recruited to its DNA binding motifs after rifampicin treatment.
As expected, ligand-activated PXR increased binding to pro-
moters of target genes. Interestingly, rifampicin also increased
PXR binding to intronic and exonic regions of target genes [170].
There was a large overlap of PXR binding sites with that of p300,
an HAT that gives an epigenetic tag for transcriptional
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activation. The authors then discovered that rifampicin treat-
ment enhanced PXR/p300 occupancy at regions near genes
involved in xenobiotic metabolism [170]. Yan et al. [169] also
found that rifampicin enhanced the recruitment of both p300
and nuclear receptor coactivator 6 (NCOA6) to the CYP3A4
promoter and knockdown of PXR suppressed their recruitment
to the promoter. p300 acetylation is also critical for ligand
activation of another nuclear receptor, FXR [171], and PXR has
been reported to be a direct target gene of FXR [172]. Therefore,
p300 acetylation may not only enhance the PXR-mediated
gene transcription but also facilitate the transcription of PXR
gene itself. In addition to p300, PXR can also directly interact
with arginine methyltransferase 1 (PRMT1), the primary methyl-
transferase that deposits the asymmetric dimethylarginine
mark [173]. ChIP analysis revealed a ligand-dependent recruit-
ment of PRMT1 to PXR regulatory regions within CYP3A4
promoter [173].
Aside from PXR’s ability to influence recruitment of
proteins involved in epigenetically tagging genomic loci,
PXR itself has been established to undergo a host of posttransla-
tional modifications including phosphorylation, SUMOylation,
ubiquitination, and acetylation [174]. These posttranslational
mechanisms that impact PXR stability may be elicited through
ligand-independent interactions. For example, the deacetylase
sirtuin-1 (SIRT1) can interact with PXR both in the presence
and absence of RXR and PXR ligands [175]. Interestingly,
resveratrol treatment (a SIRT1 activator) promotes lipogenesis
in murine primary hepatocytes, which is similar to the
effects of PCN treatment in mouse liver [175]. Furthermore,
this phenotype was alleviated by nicotinaminde treatment,
an HDAC inhibitor [175]. These data indicate that deacetylation
of PXR may promote lipogenesis independent of canonical
ligand binding. It is clear that PXR stability is governed by a
host of posttranslational modifications, but whether the
function of these modifications are initiated by EDCs and
how PXR stability influences the epigenome remain to be
determined.
Ligand-activated PXR also suppresses the transcription of
CYP7A1, a rate-limiting enzyme involved in bile acid synthesis
[176, 177]. CYP7A1 therefore plays an important role in the regu-
lation of lipid, glucose, and energy homeostasis. PXR can inter-
act with hepatic nuclear factor 4a (HNF4a), which is critical for
CYP7A1 transcription. PXR ligands can promote this interaction
and block PPARc coactivator a (PGC-1a) activation with HNF4a,
thereby inhibiting CYP7A1 gene transcription [176].
Interestingly, CYP7A1 transcription can also be epigenetically
regulated by some stimulators such as glucose [178]. Glucose
can affect histone acetylation (H3 and H4), H3K9Me2, and
H3K9Me3 of the CYP7A1 promoter [178]. Although PXR signaling
has been implicated in glucose metabolism [46, 179], it is not
clear whether PXR can also regulate CYP7A1 transcription
through epigenetic mechanisms and future works are required
to explore this possibility.
The DNA methylation and histone modification profiles of
tissue-specific transporters including OATP1B2, NTCP, BSEP,
and ABCG5/8 have also been investigated in mice [180]. Many of
these transporters including NTCP and BSEP are PXR target
genes [181]. Genome-wide DNA methylation profiling revealed
distinct hypomethylation around the transcriptional start
site of these transporters in the liver, but those regions were
hypermethylated in the kidney and cerebrum [180]. These
methylation patterns were also consistent with the tissue
distribution pattern of these transporters [180]. Histone 3
was hyperacetylated at their genetic loci in the liver but was
hypoacetylated in the kidney and cerebrum [180]. It would
be interesting to compare the methylation and acetylation
patterns in WT and PXR-deficient mice and to investigate the
impact of PXR signaling on epigenetic systems in different tis-
sues in the future. While all of these studies indicate a role of
PXR in epigenetic regulation of gene transcription, to the best
of our knowledge, there is no study investigating the effects of
EDC-mediated PXR activation on epigenetic changes that
influence CVD risk and future studies are urgently needed to
address this important topic.
Conclusion
This review aims to introduce a new, understudied role for PXR
in mediating the impact of EDC exposure on epigenetic changes
that may influence CVD risk. Numerous EDCs have been identi-
fied as PXR ligands, and we have provided an up-to-date table
including most if not all EDCs that modulate PXR activity in
humans and rodents (Table 1). However, how EDCs influence
the epigenome through PXR-dependent mechanisms is poorly
understood. In addition to the well-characterized ligand-
dependent transcriptional regulation of its target gene expres-
sion, we propose a new mechanism by which PXR may act as a
“chaperone” guiding epigenetic modifiers to the locus, thereby
allowing for transcriptional modulation (Fig. 1). EDC-mediated
epigenetic changes may not only affect the exposed individuals
but also influence diseases in successive generations. Several
lines of evidence suggest that EDCs predispose rodent and
human offspring to cardiometabolic disease risk [122, 123, 162,
165]. Since most of the gene–environment interactions do not
directly alter the DNA sequence (i.e. initiation of mutations),
these phenotypes are likely due to the passing of heritable “tag”
that can influence gene expression in the offspring. It would be
interesting to investigate the contribution of PXR to the inter-
generational and transgenerational effects of EDCs on the
development of diseases such as CVD in the offspring in the
future.
We now know that EDCs influence a wide range of disease
states, including male and female reproduction, breast develop-
ment and cancer, metabolism and obesity, and CVD [11]. These
EDCs, however, are constantly evolving; for example, the
Consumer Product Safety Improvement Act now prohibits the
sale of children’s toys containing more than 0.1% of phthalates
such as DEHP, DBP, and BBP. Although phthalate substitutes
have emerged as “safe alternatives” to those EDCs, we have not
appropriately tested these substitutes for their endocrine-
disrupting potential. Our laboratory, as well as others, has dem-
onstrated that both phthalates and phthalate substitutes have
the potential to activate PXR and induce hyperlipidemia in ani-
mal models [76, 99, 182]. Due to the growing concern posed by
EDCs, it is important for us to understand the impact of all these
EDCs on human health.
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